| Product Name |
Recombinant Human Fibroblast Growth Factor 23 (FGF23) Protein |
| Product Overview |
This recombinant human Fibroblast Growth Factor 23 (FGF23) protein includes amino acids 25-251aa of the target gene is expressed in HEK293 Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
| Target Uniprot Id |
Q9GZV9 |
| Recommended Name |
Fibroblast growth factor 23 |
| Gene Name |
FGF23 |
| Synonyms |
Fibroblast Growth Factor 23; FGF-23; Phosphatonin; Tumor-Derived Hypophosphatemia-Inducing Factor; F |
| Species |
Human |
| Predicted Molecular Mass |
30 kDa |
| Expression System |
Mammalian Cell |
| Expression Range |
25-251aa |
| Tag |
C-6His |
| Purity |
>90% |
| Formulation |
Lyophilized |
| Buffer |
Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Cancer |
| Target Function |
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. |
| Subcellular Location |
Secreted. Note=Secretion is dependent on O-glycosylation. |
| Protein Family |
Heparin-binding growth factors family |
| Associated Diseases |
Hypophosphatemic rickets, autosomal dominant (ADHR); Tumoral calcinosis, hyperphosphatemic, familial (HFTC) |
| Tissue Specificity |
Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts). |
